U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C27H29NO10
Molecular Weight 527.5199
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DAUNORUBICIN

SMILES

COC1=C2C(=O)C3=C(O)C4=C(C[C@](O)(C[C@@H]4O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)C(C)=O)C(O)=C3C(=O)C2=CC=C1

InChI

InChIKey=STQGQHZAVUOBTE-VGBVRHCVSA-N
InChI=1S/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1

HIDE SMILES / InChI

Molecular Formula C27H29NO10
Molecular Weight 527.5199
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22260166 | https://www.ncbi.nlm.nih.gov/pubmed/7932544 | https://www.ncbi.nlm.nih.gov/pubmed/13146115 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050467s070lbl.pdf

Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer. Specifically, it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma. Similar to doxorubicin, daunorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. On binding to DNA, daunomycin intercalates, with its daunosamine residue directed toward the minor groove. It has the highest preference for two adjacent G/C base pairs flanked on the 5' side by an A/T base pair. Daunorubicin should only be administered in a rapid intravenous infusion. It should not be administered intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. It should also never be administered intrathecally (into the spinal canal), as this will cause extensive damage to the nervous system and may lead to death.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CERUBIDINE

Approved Use

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Launch Date

1979
Primary
CERUBIDINE

Approved Use

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Launch Date

1979
Primary
CERUBIDINE

Approved Use

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Launch Date

1979
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
26 μg/mL
44 mg/m² 1 times / 2 days multiple, intravenous
dose: 44 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: Cytarabine
DAUNORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
637 μg × h/mL
44 mg/m² 1 times / 2 days multiple, intravenous
dose: 44 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: Cytarabine
DAUNORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
31.5 h
44 mg/m² 1 times / 2 days multiple, intravenous
dose: 44 mg/m²
route of administration: Intravenous
experiment type: MULTIPLE
co-administered: Cytarabine
DAUNORUBICIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
DAUNORUBICIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
DLT: Neutropenia, Leucopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 100%)
Leucopenia (grade 4, 100%)
Thrombocytopenia (grade 4, 16.7%)
Anemia (grade 4, 16.7%)
Sources:
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
DLT: Neutropenia, Leucopenia...
Disc. AE: Cardiac failure...
Dose limiting toxicities:
Neutropenia (grade 4, 100%)
Leucopenia (grade 4, 50%)
AEs leading to
discontinuation/dose reduction:
Cardiac failure (grade 5, 16.7%)
Sources:
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 27-87
Health Status: unhealthy
Age Group: 27-87
Sex: M+F
Sources:
Disc. AE: Skin toxicity...
AEs leading to
discontinuation/dose reduction:
Skin toxicity (4.2%)
Sources:
20 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 20 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 20 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, 38.7
Health Status: unhealthy
Age Group: 38.7
Sex: M+F
Sources:
Disc. AE: Skin eruption...
AEs leading to
discontinuation/dose reduction:
Skin eruption (0.9%)
Sources:
80 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 80 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 80 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M+F
Sources:
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M+F
Sources:
DLT: Acute diverticular perforation...
Dose limiting toxicities:
Acute diverticular perforation
Sources:
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Disc. AE: Ejection fraction decreased, Prolonged neutropenia...
Other AEs: Granulocytopenia, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Ejection fraction decreased (5.3%)
Prolonged neutropenia (2.6%)
Other AEs:
Granulocytopenia (grade 4, 21%)
Thrombocytopenia (grade 4, 8%)
Febrile neutropenia (grade 4, 11%)
Sources:
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Disc. AE: Infusion related reaction, Myelosuppression...
AEs leading to
discontinuation/dose reduction:
Infusion related reaction (acute)
Myelosuppression (severe)
Cardiotoxicity
Congestive heart failure
Hepatic impairment
Reaction anaphylactic anaphylactoid (grade 3-5)
Sources:
AEs

AEs

AESignificanceDosePopulation
Leucopenia grade 4, 100%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Neutropenia grade 4, 100%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Anemia grade 4, 16.7%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Thrombocytopenia grade 4, 16.7%
DLT
190 mg/m2 1 times / 3 weeks multiple, intravenous
Highest studied dose
Dose: 190 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 190 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Neutropenia grade 4, 100%
DLT
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Leucopenia grade 4, 50%
DLT
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Cardiac failure grade 5, 16.7%
Disc. AE
155 mg/m2 1 times / 3 weeks multiple, intravenous
MTD
Dose: 155 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 155 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 10
Health Status: unhealthy
Age Group: 10
Sex: M+F
Sources:
Skin toxicity 4.2%
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy, 27-87
Health Status: unhealthy
Age Group: 27-87
Sex: M+F
Sources:
Skin eruption 0.9%
Disc. AE
20 mg/m2 1 times / 2 weeks multiple, intravenous
Recommended
Dose: 20 mg/m2, 1 times / 2 weeks
Route: intravenous
Route: multiple
Dose: 20 mg/m2, 1 times / 2 weeks
Sources:
unhealthy, 38.7
Health Status: unhealthy
Age Group: 38.7
Sex: M+F
Sources:
Acute diverticular perforation DLT, Disc. AE
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M+F
Sources:
Prolonged neutropenia 2.6%
Disc. AE
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Ejection fraction decreased 5.3%
Disc. AE
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Febrile neutropenia grade 4, 11%
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Granulocytopenia grade 4, 21%
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Thrombocytopenia grade 4, 8%
100 mg/m2 1 times / 3 weeks multiple, intravenous
Studied dose
Dose: 100 mg/m2, 1 times / 3 weeks
Route: intravenous
Route: multiple
Dose: 100 mg/m2, 1 times / 3 weeks
Sources:
unhealthy, 63
Health Status: unhealthy
Age Group: 63
Sex: M+F
Sources:
Cardiotoxicity Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Congestive heart failure Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Hepatic impairment Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Infusion related reaction acute
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Reaction anaphylactic anaphylactoid grade 3-5
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Myelosuppression severe
Disc. AE
50 mg/m2 1 times / 4 weeks multiple, intravenous
Recommended
Dose: 50 mg/m2, 1 times / 4 weeks
Route: intravenous
Route: multiple
Dose: 50 mg/m2, 1 times / 4 weeks
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 203 uM]
yes [Ki 49.4 uM]
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
[Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells].
1999 Sep
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
2000 Aug 1
Focal degradation of cytoplasmic organelles in cardiomyocytes during regenerative and plastic myocardial insufficiency.
2000 Dec
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
2000 Jul
Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group.
2000 Jul
Comparison of anthracycline-induced death of human leukemia cells: programmed cell death versus necrosis.
2002 Dec
Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.
2002 Feb
Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
2002 Feb
Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma.
2002 Feb
A novel, extraneuronal role for cyclin-dependent protein kinase 5 (CDK5): modulation of cAMP-induced apoptosis in rat leukemia cells.
2002 Jun 7
Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, depletion of ATP and necrotic cell death in human leukaemic cells.
2002 May
Resistance of bcr-abl-positive acute lymphoblastic leukemia to daunorubicin is not mediated by mdr1 gene expression.
2002 Nov
Vincristine neurotoxicity in the presence of hereditary neuropathy.
2003 Jan
Human intestinal absorption of imidacloprid with Caco-2 cells as enterocyte model.
2004 Jan 1
Patents

Sample Use Guides

Usual Adult Dose for Acute Nonlymphocytic Leukemia: Under 60 years of age: 45 mg/m2 IV over 2 to 5 minutes once a day on days 1, 2, and 3 for the first course and on days 1 and 2 for subsequent courses) with cytosine arabinoside (ara-C) intravenously once a day (usually for 7 days for the first course and 5 days for subsequent courses) as remission induction therapy.
Route of Administration: Intravenous
In order to determine the viability of HL-60, K562, THP-1, and HEK293T cells, they were trypsinized, counted, and seeded into 96-well plates and were treated with serial dilutions (0.0001, 0.001, 0.01, 0.1, 1 mkM) of DNR (Daunorubicin). Cell viability was determined 48 h after DNR treatment using the luminescent cell viability assay (Promega) through luminescence testing by BMG NOVOstar machine.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:22:58 GMT 2025
Edited
by admin
on Mon Mar 31 18:22:58 GMT 2025
Record UNII
ZS7284E0ZP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DAUNORUBICIN
HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
VYXEOS COMPONENT DAUNORUBICIN
Preferred Name English
FI 6339
Code English
RP 13057
Code English
EPIRUBICIN IMPURITY D
Common Name English
DAUNORUBICIN [MI]
Common Name English
(8S,10S)-8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-6,8,11-TRIHYDROXY-1-METHOXY-7,8,9,10-TETRAHYDROTETRACENE-5,12-DIONE
Common Name English
DAUNORUBICIN [HSDB]
Common Name English
RP-13057
Code English
5,12-NAPHTHACENEDIONE, 8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL))OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-, (8S-CIS)-
Common Name English
DAUNOMYCIN
Common Name English
FI-6339
Code English
Daunorubicin [WHO-DD]
Common Name English
NSC-83142
Code English
EPIRUBICIN HYDROCHLORIDE IMPURITY D [EP IMPURITY]
Common Name English
EPIRUBICIN HYDROCHLORIDE IMPURITY, DAUNORUBICIN- [USP IMPURITY]
Common Name English
VALRUBICIN IMPURITY, DAUNORUBICIN [USP IMPURITY]
Common Name English
DAUNORUBICIN [MART.]
Common Name English
DOXORUBICIN HYDROCHLORIDE IMPURITY A [EP IMPURITY]
Common Name English
(1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE
Common Name English
DAUNORUBICIN [ORANGE BOOK]
Common Name English
DAUNORUBICIN [VANDF]
Common Name English
daunorubicin [INN]
Common Name English
DAUNOMYCIN [IARC]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175414
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
NCI_THESAURUS C1594
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
FDA ORPHAN DRUG 265808
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
WHO-ATC L01DB02
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
NDF-RT N0000007530
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
WHO-ATC L01XY01
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
NDF-RT N0000000176
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
NDF-RT N0000007530
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
LIVERTOX NBK548259
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
NDF-RT N0000007530
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
EU-Orphan Drug EU/3/11/942
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
WHO-VATC QL01DB02
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
Code System Code Type Description
HSDB
5095
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
INN
2257
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
EVMPD
SUB06917MIG
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
WIKIPEDIA
DAUNORUBICIN
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
ChEMBL
CHEMBL178
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
DRUG BANK
DB00694
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
PUBCHEM
30323
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
EPA CompTox
DTXSID7022883
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
NCI_THESAURUS
C62091
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
MESH
D003630
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
IUPHAR
7063
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
DAILYMED
ZS7284E0ZP
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
NSC
83142
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
MERCK INDEX
m4104
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY Merck Index
FDA UNII
ZS7284E0ZP
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
SMS_ID
100000086006
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
CAS
20830-81-3
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
CHEBI
41977
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
RXCUI
3109
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY RxNorm
DRUG CENTRAL
786
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
ECHA (EC/EINECS)
244-069-7
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
CHEBI
64677
Created by admin on Mon Mar 31 18:22:58 GMT 2025 , Edited by admin on Mon Mar 31 18:22:58 GMT 2025
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> SUBSTRATE
TRANSPORTER -> INHIBITOR
Related Record Type Details
PARENT -> IMPURITY
PARENT -> IMPURITY
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC